Recent Finacing
Recent Raise
POINT Biopharma develops precision radioligand therapies and radiopharmaceuticals, advancing 177Lu‑PSMA PNT2002 (Phase 3 for metastatic castrate‑resistant prostate cancer) and operating a 77,000 sqft radioligand manufacturing facility in Indianapolis.